期刊文献+

细胞减灭术加腹腔热灌注化疗治疗卵巢癌腹膜转移癌的临床研究 被引量:26

Clinical Investigation on Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy on Patients with Peritoneal Carcinomatosis from Epithelial Ovarian Cancer
下载PDF
导出
摘要 目的研究细胞减灭术(CRS)加腹腔热灌注化疗(HIPEC)治疗卵巢癌腹膜转移癌的疗效及安全性。方法 46例晚期卵巢癌腹膜癌(A组FIGOⅢc/Ⅳ期16例,B组复发性30例)患者接受了CRS+HIPEC治疗,分析其临床资料,主要终点指标为总生存期,次要指标为安全性。结果 A、B两组患者的中位总生存期(OS)分别为74.0月和57.5月(P=0.68)。腹膜癌指数(PCI)≤20(n=24)和〉20(n=22)的中位OS分别为76.6和38.5月(P=0.01)。CC 0~1分和CC 2~3分的中位OS分别为79.5和24.3月(P=0.00)。对复发性卵巢癌腹膜癌患者来说,铂类敏感型和耐药型患者的中位OS分别为65.3和20.0月(P=0.05)。无围手术期死亡病例,5例患者出现术后并发症。多因素分析显示,CC 0~1分、术后化疗≥6周期为改善生存的独立预后因素。结论 CRS+HIPEC可延长卵巢癌腹膜癌患者的总生存期,安全可行。 Objective To evaluate the efficacy and safety of cytoreductive surgery(CRS) plus hyperthermic intraperitoneal chemotherapy(HIPEC) on patients with peritoneal carcinomatosis(PC) from advanced/recurrent epithelial ovarian cancer(EOC). Methods We included 46 patients with advanced EOC(FIGO stage Ⅲc/Ⅳ, n=16, Group A) and recurrent EOC with PC(n=30, Group B) treated by CRS+HIPEC procedures. The primary endpoint was overall survival(OS) from the first treatment to disease-related death. The secondary endpoints were safety profiles. Results The median OS was 74.0 months(95%CI: 8.5-139.5) in Group A vs. 57.5 months(95%CI: 29.8-85.2) in Group B(P=0.68). The median OS for patients with PCI≤20 vs. PCI〉20 were 76.6 months(95%CI: 56.5-96.7) vs. 38.5 months(95%CI: 24.2-52.8)(P=0.01). The median OS for patients with CC0-1 vs. CC2-3 were 79.5 months(95%CI: 64.8-94.2) vs. 24.3 months(95%CI: 13.9-34.7)(P=0.00). In the recurrent group, the median OS were 65.3 months(95%CI: 42.6-88.9) for platinum-sensitive patients vs. 20.0 months(95%CI: 14.5-23.5) for platinum resistant patients(P=0.05). There was no perioperative death. Postoperative adverse events occurred in five patients. Multivariate analysis revealed that CC0-1 and chemotherapy ≥ six cycles were the independent factors for OS improvement. Conclusion For patients with PC from advanced/recurrent EOC, CRS plus HIPEC could improve the OS with acceptable safety profiles, particularly for advanced EOC PC patients.
出处 《肿瘤防治研究》 CAS CSCD 北大核心 2016年第4期282-286,共5页 Cancer Research on Prevention and Treatment
基金 2013年湖北省医学领军人才培养工程项目(鄂卫生计生发[2013]4号) 教育部博士点基金(20120141110042)
关键词 卵巢癌 腹膜转移癌 细胞减灭术 腹腔热灌注化疗 Epithelial ovarian cancer(EOC) Peritoneal carcinomatosis(PC) Cytoreductive surgery(CRS) Hyperthermic intraperitoneal chemotherapy(HIPEC)
  • 相关文献

参考文献23

  • 1Hennessy BT, Coleman RL, Markman M. Ovarian cancer[J]. Lancet, 2009, 374(9698): 1371-82. 被引量:1
  • 2McGuire WE Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxei and cisplatin in patients with stage Ill and stage IV ovarian cancer[J]. N Engl J Med, 1996, 334(1): 1-6. 被引量:1
  • 3Ozols RF, Bundy BN, Greer BE, et al. Phase IH trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage UI ovarian cancer: a Gynecologic Oncology Group study[J]. J Clin Oncol, 2003, 21(17): 3194-200. 被引量:1
  • 4Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis[J]. J Clin Oncol, 2002, 20(5): 1248-59. 被引量:1
  • 5van Driel W J, Lok CA, Verwaal V, et al. The role of hyperthermic intraperitoneal intraoperative chemotherapy in ovarian cancer[J]. Curr Treat Options Oncol, 2015, 16(4): 14. 被引量:1
  • 6Yonemura Y, Canbay E, Endou Y, et al. Peritoneal cancer treatment[J]. Expert Opin Pharmacother, 2014, 15(5): 623-36. 被引量:1
  • 7Maggiori L, Elias D. Curative treatment of colorectal peritoneal carcinomatosis: current status and future trends[J]. Eur J Surg Oncol, 2010, 36(7): 599-603. 被引量:1
  • 8Sugarbaker PH. Five reasons why cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy must be regarded as the new standard of care for diffuse malignant peritoneal mesotheliomia[J]. Ann Surg Oncol, 2010, 17(6): 1710-2. 被引量:1
  • 9Chua TC, Moran B J, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendieeal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy[J]. J Clin Oncol, 2012, 30(20): 2449-56. 被引量:1
  • 10Huang CQ, Yang X J, Yu Y, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for patients with peritoneal carcinomatosis from colorectal cancer: A phase II study from a Chinese center[J]. PLoS One, 2014, 9(9): e108509. 被引量:1

二级参考文献60

共引文献107

同被引文献235

引证文献26

二级引证文献141

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部